Assumed costs of ART delivery.

#ARV and ART cost assumptions are based on country-specific estimates of ARV and service delivery cost and a fixed cost for laboratory and end-of-life treatment of opportunistic infections. The shown average ‘Total’ is weighted across Global Fund-supported AIDS programs according to their number of patients at end-2009. The shown weighted average costs of the individual components do not add up to the weighted average total cost per patient, because of considerable variation among countries in the cost of ARVs and treatment delivery.

本研究所采用的抗逆转录病毒药物（ARV）与抗逆转录病毒治疗（ART）成本假设，基于各国专属的抗逆转录病毒药物及服务供给成本估算，以及实验室检测与机会性感染终末期治疗的固定成本。文中展示的“总平均”成本，是依据2009年末全球基金（Global Fund）支持的艾滋病项目的患者数量进行加权计算所得。由于各国在抗逆转录病毒药物成本与治疗实施成本上存在显著差异，各单项成本的加权平均值之和，无法与患者人均总加权平均成本相等。